Liège, Belgium - 23 June 2022, - regulated information – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Hyloris Pharmaceuticals SA (Euronext Brussels : HYL) publishes the following information:
| Total amount of share capital on 05 April 2022 | EUR 134,001.87 |
| Total number of shares with voting rights on 05 April 2022 | 26.800.374 |
| Total number of new shares issued on 22 June 2022 | 1.200.000 |
| Total amount of share capital on 22 June 2022 | EUR 140,001.87 |
| Total number of shares with voting rights on 22 June 2022 | 28.000.374 |
| Total number of voting rights (denominator) on 22 June 2022 | 28.000.374 |
| Total number of attributed warrants on 5 April 2022 | 1.699.500 |
| Total of exercised warrants on 22 June 2022 | 1.200.000 |
| Total number of cancelled warrants | 1.875 |
| Total number of new warrants (2022 Plan) on 22 June 2022 (1) | 213.500 |
| Total number of shares with voting rights that can be issued following the exercise of the attributed warrants. | 711.125 |
| (1) replacing the cancelled warrants from 2020 ESOP Warrants |
About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 14 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Outside of its core strategic focus, the Company also has 4 high barrier generic products in development and registration phase. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.
For more information contact :
Hyloris Pharmaceuticals, Investors and Media
investorrelations@hyloris.com
Disclaimer and forward-looking statements
Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Attachment
